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The versatile enzyme Araf51 allowed eﬃcient
synthesis of rare pathogen-related
β-D-galactofuranosyl-pyranoside disaccharides
Ilona Chlubnová,a,b,c Blanka Králová,c Hana Dvořáková,d Petr Hošek,c
Vojtěch Spiwok,c Dominik Filipp,e Caroline Nugier-Chauvin,*a,b
Richard Daniellou†a,b and Vincent Ferrières*a,b
The preparation of galactofuranosyl-containing disaccharidic parts of natural glycoconjugates was per-
formed according to a chemo-enzymatic synthesis. Our goals were ﬁrstly to develop an alternative
approach to standard chemical strategies by limiting the number of reaction and puriﬁcation steps, and
secondly to evaluate the scope of the Araf51 biocatalyst to transfer a galactofuranosyl moiety to a set of
pyranosidic acceptors diﬀering from each other by the series, the anomeric conﬁguration as well as the
conformation. The study of binding mode of the resulting disaccharides was also performed by molecular
modeling and showed signiﬁcant diﬀerences between (1→2)- and (1→6)-linked disaccharides.
Introduction
The complex heterogeneity of carbohydrates in living systems
is a direct result of several carbohydrate characteristics: the
ability of diﬀerent types and numbers of sugar residues to
form glycosidic bonds with one another, the type of anomeric
linkage, the position and the absence or presence of branch-
ing, the more or less flexible conformations of the resulting
oligo-, polysaccharides or glycoconjugates,1,2 and the size of
the monosaccharidic ring.3,4 Indeed, sugars exhibit significant
diﬀerences depending on whether they are present as pyrano-
sides or as furanosides. It is now well established that the
importance of the furanose ring in biology can no longer be
understated. A key characteristic of furanose ring systems
is their higher flexibility compared to that of their pyranosidic
counterparts,5 and this profoundly influences their role in bio-
logical processes.6 While furanosyl-containing oligosacchar-
ides are crucial constituents of surface glycoconjugates in cell
walls of bacteria,7–9 fungi10 and parasitic11,12 microorganisms,
including some clinically significant pathogens, with an excep-
tion of 2-deoxy-D-ribose and D-ribose, furanosides are comple-
tely absent from mammals. This makes them interesting
targets for development of new therapeutics.
A major limitation preventing the use of oligosaccharides
as therapeutics is the diﬃculty in producing suﬃcient
amounts of these molecules in a desired purity. The isolation
of these compounds from biological sources tends to be low
yielding and presents the risk of contamination from infec-
tious agents.13 Although progress in the chemical synthesis of
oligosaccharides has been made14–20 and synthesis of docosana-
arabinofuranoside realized by Lowary’s research team21 is
impressive evidence, this approach still remains a challenge.
The chemical synthesis requires stereo- and regioselective
control of glycosidic bond formation, thus multiple protection
and deprotection schemes are needed to achieve the required
selectivity. Low yields of the desired products are also a result
of the diﬃculty in purifying the deprotected compound along
with product loss during each step of a multistep synthesis.13,22
Nature’s solution to the assembly of glycosidic bonds are
enzymes belonging to the families of glycosyl transferases and of
glycosidases. These enzymes have therefore enormous potential
for the synthesis of biologically relevant carbohydrate struc-
tures.23 These biocatalysts oﬀer a significant advantage over their
chemical counterparts in their ability to form a specific glycosidic
linkage in the presence of other reactive functional groups.22
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In this context, only few groups have been interested in
the chemo-enzymatic synthesis of furanosyl-containing
conjugates.3,24–27 Furanosyl transferases are however rare and
require both nucleotide-diphospho (NDP)-sugars as donors
and suitable acceptors.28–30 Another approach, recently pro-
posed by Thorson, is based on the glycosyl transferase reversi-
bility, that uses simple glycosides as precursors of NDP-sugars
for further transfer onto more complex natural products.31,32
To the best of our knowledge, this strategy was not applied for
the synthesis of furanosides. Recently, our team developed an
enzyme-based protocol for the preparation of di- and oligofura-
nosides using the thermophilic Araf51 as biocatalyst.33 Consid-
ering the structural similarity between L-arabino- and
D-galactofuranosyl (D-Galf ) entities, and the wide presence of
D-Galf residues in natural glycoconjugates and polysaccharides,
we now propose to expand the chemo-enzymatic methodology
to transglycosylation reactions in order to transfer a galacto-
furanosyl entity to a variety of pyranosidic acceptors (Fig. 1).
These substrates were chosen so as to perform the synthesis of
furanosyl-pyranoside sequences relevant to pathogenic micro-
organisms3 as well as to estimate the specificity of this enzyme
towards carbohydrate acceptors. As we expected that such pyra-
nosides are resistant to hydrolysis by the furanosidase Araf51,
the presence of the pNP group in the anomeric position was
envisaged to enable simple UV detection of reaction products.
Moreover, the D-gluco- (D-Glcp), D-galacto- (D-Galp) and D-man-
nopyranosidic (D-Manp) epimers, as well as their anomeric
configurations, oﬀer stereochemical variations that may influ-
ence the fate of the coupling process. Finally, we made a focus
on the L-rhamnopyranoside (L-Rhap) 8 for structural and bio-
logical reasons but also because it displays a 1C4 conformation
instead a 4C1 one observed for other acceptors 2–7.
Results
In the first place, unavailability of the −1 subsite of Araf51 to
pyranosidic acceptors was confirmed spectrophotometrically
(405 nm) by incubation of individual pNP pyranosides 2–8
with the enzyme for 2 h at 60 °C in a phosphate buﬀer at pH
7.4. No release of p-nitrophenolate was recorded, indicating
that these compounds cannot act as donors, thus confirming
our first hypothesis. Subsequently, to screen enzyme readiness
to catalyze transglycosylation, individual analytical-scale reac-
tions were performed starting from donor 1 and each of pNP
glycopyranoside, and in the presence of Araf51. Monitoring by
thin layer chromatography showed the formation of disacchar-
ides when the donor 1 was incubated with an equal molar
quantity or with a 5-fold molar excess of pyranosidic acceptor,
after only short incubation periods (5–20 min). These com-
pounds resulted from both self-condensation of 1 and desired
transglycosylation reactions.
As a model of biocatalyzed coupling, the progress of the
reaction of 1 with 2 (pNP α-D-Glcp) was monitored by HPLC
(Fig. 2). Between 5 and 20 minutes, digalactofuranosides con-
stituted the main reaction products.33 At the same time, these
products of self-condensation were hydrolyzed more rapidly
than furanosyl-pyranoside disaccharides, which resisted to
hydrolysis for more than 3 h. This could be explained by the
structures of the resulting disaccharides which significantly
diﬀer from those of natural substrates of the enzyme. In the
present model reaction, traces of trisaccharides were observed
from the early stage of the reaction (5–10 min) and were con-
firmed by mass spectrum analysis, but precise structures
could not be elucidated. Importantly, when the ratio donor/
acceptor was increased to 1 : 10, no products of self-conden-
sation were detected. Moreover, synthesis of furano-pyrano-dis-
accharides was strongly favored over hydrolysis of 1. After
careful chromatographic purification, two main disaccharides
9 and 10 were isolated and their structures were elucidated by
NMR spectroscopy. The major product 9 was obtained in the
yield of 44%. It exhibited an intense three-bond coupling in
the 13C–1H (HMBC) spectrum between H-1′ (5.09 ppm) and C-2
(79.2 ppm) as well as C-1′ (109.4 ppm) and H-2 (3.69 ppm) and
was identified as pNP β-D-galactofuranosyl-(1→2)-α-D-glucopyr-
anoside 9 (Fig. 2). The second regioisomer, isolated in 34%
yield, presented a correlation between H-1′ (5.24 ppm) and C-3
(79.4 ppm) as well as between C-1′ (108.3 ppm) and H-3
(3.96 ppm). The compound was identified as (1→3)-linked dis-
accharide 10. The time-course analysis monitored by HPLC
revealed that the (1→3)-disaccharide 10 was kinetically syn-
thesized, followed by the formation of the (1→2)-isomer 9.
This monitoring also showed that these compounds dis-
appeared with time in favor of a third regioisomer. The yield of
the latter reached its maximum after 4 hours of reaction and it
was still present after 24 hours. The precise nature of the
corresponding glycosidic linkage could however not be clearly
elucidated. As a result, the overall yield of transglycosylation
reached a maximum, slightly greater than 80%, between 5 and
20 minutes. In the present model reaction, traces of trisacchar-Fig. 1 Structure of glycosyl donor 1 and acceptors 2–8.
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ides were observed from the early stage of the reaction
(5–10 minutes) and confirmed by mass spectrum analysis, but
precise structures could not be elucidated.
Under similar conditions, using the β-glucopyranoside 3 as
an acceptor (Fig. 2), and after 20 minutes of reaction, three dis-
accharides were chromatographically separated: pNP β-D-Galf-
(1→2)-β-D-Glcp 11, pNP β-D-Galf-(1→3)-β-D-Glcp 12, and pNP
β-D-Galf-(1→6)-β-D-Glcp 13 were isolated in 26%, 25% and 30%
yields, respectively. The time-course analysis revealed that the
(1→2)-linked regioisomer 11 was the major kinetic product
and is present together with the (1→3)-linked regioisomer 12
from the first minutes of the reaction. From about 15 minutes,
the (1→6)-linked regioisomer 13 was formed and became the
prevalent one after 1 hour. It was still detected in 15% yield
after 24 hours. It is interesting to note that, when 12 was incu-
bated with the biocatalyst and an excess of 3, it was trans-
formed into 13. This emphasizes the striking stability of this
(1→6)-bond in the presence of the furanosyl hydrolase Araf51.
To go further with this methodology, we applied the Araf-
51-assisted synthesis of furanosyl-containing disaccharides to
three other families of acceptors. The use of galactosidic
acceptors 4 and 5 did not fundamentally change the obser-
vations previously exposed with the gluco series. Three disac-
charides with (1→2)- (14), (1→3)- (15), and (1→4)-linkage (16)
were obtained from the α-anomer 4 and isolated in 73%
overall yield (Table 1, entry 1). Substrate 5, characterized by a
β-configuration, aﬀorded only the (1→2)- (17) and (1→6)-disac-
charides (18) in a near equimolecular ratio and in a 52%
overall yield (entry 2).
On the other hand, the reaction with the α-mannopyrano-
side 6 (entry 3) was relatively rapid compared to other pyrano-
sidic acceptors and the degree of hydrolysis of formed
disaccharides was slightly higher. The reaction in a preparative
scale was thus carried out for only 10 minutes. pNP β-D-Galf-
(1→6)-α-D-Manp 19 was obtained in 15% yield. 2-D NMR ana-
lyses confirmed that three other regioisomers were obtained as
a mixture in an overall yield of 43%. The time-course analysis
monitored by TLC revealed that these regioisomers are readily
formed from the first minutes of reaction with the maximum
yields reached between 5 and 10 minutes. The (1→6)-linked
regioisomer 19 was formed from about 5 minutes of reaction.
The transglycosylation with the β-anomer 7 was apparently
slower than that of the α-anomer and the conversion of pNP
β-D-Galf still did not reach a maximum after two hours of reac-
tion. However, the degree of hydrolysis was quite low, similarly
to the other pNP pyranosides. After 25 minutes of the prepara-
tive-scale reaction, two regioisomers were isolated (entry 4). pNP
β-D-Galf-(1→4)-β-D-Manp 20 was obtained in a very high yield of
49%. The second regioisomer 21, identified as the (1→6)-disac-
charide, was isolated in 16% yield. The time-course analysis
confirmed kinetic preferences for the (1→4)-linked disaccharide
20. In about 40 minutes of reaction, both regioisomers were
present equivalently. At the end of 2 hours incubation, the
favoured (1→6)-linked regioisomer 21 prevailed. Structures were
unambiguously established according to NMR data.
Finally, we also studied the L-rhamnopyranoside 8 since it
presents significantly diﬀerent reactivity and because it is
widely found in Nature. While three disaccharides were
Fig. 2 Progress of the reaction of 1 with 2 or 3 catalyzed by Araf51.
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observed after 20 minutes of the biocatalytic process, exclusively
one regioisomer 22, characterized by a (1→4)-connection, was
indeed isolated and in a fairly good 38% yield (entry 5). Evi-
dence of the precise structure was established on the basis of
NMR data. More specifically, the C-4 signal in the starting sub-
strate 8 (δC-4 = 71.4 ppm) was shifted to 77.8 ppm within the dis-
accharide 22, thus demonstrating the (1→4)-coupling, and this
result was corroborated by 2D NMR experiments.
Discussion
All results obtained for the transfer of a galactofuranosyl
residue to pyranosidic acceptors mediated by the arabinofura-
nosidase Araf51 underline the ability of this enzyme to accept
within its +1 subsite all the seven tested pyranosidic acceptors.
Importantly, the anomeric configuration of the latter modu-
lated the behavior of the furanosyl transfer. Usually, the (1→2)-
disaccharides were the most common in the gluco and galacto
series, and readily formed and stable. The (1→3) linkage was
formed subsequently and was also frequently presented in
these series. Interestingly, none of these α-anomers displayed
the (1→6)-connection although for the β-anomers, it rep-
resents the major thermodynamically formed linkage. In
Nature, exo-acting α-L-arabinofuranosidases release the arabi-
nosyl decorations at C-2 and C-3 position of arabinogalactans
and arabinoxylans from a range of plant structural polysac-
charides, where both the galactose and xylose moieties are pre-
sented in a β-D-pyranose form. Thus, considering the
structural similarity of xylose and glucose, the transglycosyla-
tion preferences correspond to the hydrolytic activity on
natural substrates.
Starting from β-D-mannopyranoside and α-L-rhamnopyrano-
side, the kinetically preferred linkage was the (1→4). It results
from this observation that the adopted conformations within
the active site of Manp and Rhap derivatives vary to some
extent compared to the glucosidic and galactosidic mono-
saccharides. Thus the axial C-2 hydroxyl group in mannose, in
contrast to glucose, seems to impact the conformation within
the active site more markedly than the orientation of C-4 OH
group distinguishing glucose from galactose. Overall, in all the
three series where both anomers were tested (D-Glcp, D-Galp,
D-Manp), the reactions involving the α-anomer proceeded
markedly faster than those of their β-anomeric counterparts.
The time-course analyses also revealed the crucial eﬀect of the
reaction time on the ratio of regioisomers formed in individual
reactions. Thus, in most of cases, it is possible to isolate either
kinetic or thermodynamic disaccharide with a very low quan-
tity of the other regioisomer with respect to the time-course of
the reaction.
In order to elucidate binding modes of acceptors 2–7 in
transglycosylation reactions, complexes of Araf51 with all puta-
tive transglycosylation products were subjected to molecular
dynamics simulations (24 × 10 ns). Each putative product was
docked into the active site by rigid fit of its Galf moiety onto
the Araf moiety in the experimental structure. The pyranosyl
and pNP-moieties were adjusted manually before the simu-
lation. The results of simulations for disaccharides 11, 14, 17
and 18 are shown in Fig. 3. These selected products showed
stable binding in the active site illustrated by low root-mean-
square deviation (RMSD). The results also demonstrated that
binding modes of (1→2) products are very similar. The pNP-
moiety is oriented perpendicularly to the access of the active
site. On the other hand, the pNP-moiety in 18 [β-D-Galf-(1→6)-
Table 1 Araf51-mediated synthesis of disaccharides 9–22 using pNP β-D-Galf 1 as donor and the linkages identiﬁed in individual regioisomers
together with the isolated yields after two hours of reaction
Product (yield, %)
Entry Acceptor Time (min) (1→2) (1→3) (1→4) (1→6) Overall yield (%)
1 4 (α-D-Galp) 20 14 (41) 15 16 73
(32)
2 5 (β-D-Galp) 20 17 (27) 18 (25) 52
3 6 (α-D-Manp) 15 Mixture (1→2/3/4) (43) 19 (15) 58
4 7 (β-D-Manp) 25 20 (49) 21 (16) 65
5 8 (α-L-Rhap) 20 22 (38) 38
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β-D-Galp], as an example of (1→6) product, is placed along the
axis of the active site. The fact that the pNP-moiety may orient
in diﬀerent angles explains relatively broad acceptor specificity.
Most other putative products have shown high RMSD which
indicate either inability of the product to bind into the active
site or incorrect docking. Unfortunately, attempts to quantita-
tively predict acceptor preferences from molecular simulations
or free-energy methods were not successful (not shown).
Among the disaccharides prepared throughout this part,
several display a configuration reported from uncommon cell
wall glycoconjugates of some pathogenic species. Galactofura-
nosyl residue connected to D-Glcp moiety through the (1→3)-
linkage has been identified e.g. in Streptococcus species,34 the
one with the (1→6)-linkage is reported from Escherichia coli
K-12 strain.35 The (1→3)-linkage to D-Galp was identified in
Fibrobacter succinogenes36 or in the O-antigen repeating unit of
Klebsiella pneumoniae.36 In Mycobacterium species37–40 and
Plesiomonas shigelloides,41 β-D-Galf is connected to L-Rhap
through the (1→4)-linkage. The sequence β-D-Galf-(1→2)-
D-Manp is present in many microorganisms, among the patho-
gens notably Cryphonectria parasitica42 or Trichoderma.43
β-D-Galf-(1→3)-D-Manp is frequent in Aspergillus,44 Trypano-
soma cruzi12,45 and Leishmania,11 β-D-Galf-(1→6)-D-Manp e.g. in
Aspergillus,44 Leishmania11 or Paracoccidioides brasiliensis.46
Conclusions
A chemo-enzymatic synthesis of galactofuranosyl-containing
disaccharides was proposed mediated by the thermophilic ara-
binofuranosidase Araf51. We have first demonstrated that a
large excess of acceptor allowed overcoming the self-conden-
sation side reaction. Secondly, transglycosylation products
were obtained in the early stage of the biocatalyzed process
and increased reaction times did not aﬀect the target furano-
syl-pyranoside disaccharides since the degree of hydrolysis of
the latter remained very low. These factors together were fruit-
ful from a synthetic point of view. Consequently, and with
regard to the very good yields obtained with the assistance of
the hydrolytic furanosidase Araf51, this chemo-enzymatic
approach constitutes a very interesting alternative to multi-step
chemical synthesis of various mimetics of biologically signifi-
cant structures. The +1 subsite of Araf51 was able to recognize
simple glycopyranosides as acceptors, even a Rhap derivative
and its 1C4 conformation. Among targets were prepared disac-
charides biosynthesized by Mycobacteria, Leishmania, Trypano-
soma or Paracoccidioides microorganisms.
Experimental section
General remarks
Prior to NMR analysis, fractions were exchanged in D2O
(99.9% purity) at room temperature with intermediate freeze-
drying, and then dissolved in 400 μL of D2O. 1H, 13C, COSY,
HSQC, HMBC, TOCSY and NOESY NMR spectra were recorded
at the Laboratory of NMR spectroscopy (ICT Prague, Czech
Republic) on a Bruker 600 Avance spectrometer equipped with
a cryoprobe at 600 MHz for 1H and 125 MHz for 13C, and on a
Bruker ARX 400 at 400 MHz for 1H, 100 MHz for 13C at ENSCR
(France). Chemical shifts are given in δ-units (ppm). Coupling
constants J are given in Hz.
Fig. 3 Predicted binding modes of 11, 14, 17 and 18 by 10 ns molecular dynamics simulations. The ﬁgure shows predicted binding modes at the
end of each simulation (left) and corresponding RMSD proﬁles (right). These were obtained by ﬁtting protein Cα atoms and calculating RMSD for the
product.
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The HRMS were measured at the Centre Régional de
Mesures Physiques de l’Ouest (CRMPO, Université de Rennes
1, France) with a MS/MS ZabSpec TOF Macromass using
m-nitrobenzylic alcohol as the matrix and accelerated caesium
ions for ionization and at the Laboratory of Mass Spectrometry
(ICT Prague, Czech Republic) using a Q-TOF Micro (Waters,
USA), where electrospray-ionisation mass spectra (ESI-MS)
were recorded on samples dissolved in MeOH injected in a
volume of 2–5 μL into a flow (100 μL min−1) of MeOH. Sample
cone voltage was 42 V and the source temperature was 150 °C.
Measurements were performed in positive ([M + Na]+ ion
detection) mode in the range of 100–1000 Da. Finally, at the
Mass Spectrometry Group (Institute of Organic Chemistry and
Biochemistry, Academy of Sciences of the Czech Republic) on
LTQ-Orbitrap XL (THERMO), where ESI+ spectra were recorded
on samples dissolved in MeOH–H2O (1 : 1), sample cone
voltage was 40 V.
Thin layer chromatography (TLC) analyses were conducted
on Kieselgel 60 F254 (Merck) plates with 0.2 mm layer thick-
ness. Spots were visualized by UV (254 nm) and by exposure to
0.2% w/v orcinol in H2SO4 (20% v/v) in ethanol. For column
chromatography, either Si 60 (40–63 μm) Silica gel or pre-
packed Chromabond®Flash RS 15 SiOH columns (Macherey-
Nagel) were used.
Gel permeation chromatography was performed on P-2 Bio-
Gel (Bio-Rad) using FPLC system consisting of a solvent deliv-
ery system Biologic F40 DuoFlow, Biologic QuadTec UV-Vis
Detector and Biologic BioFrac Fraction Collector (all Bio-Rad).
Deionized filtrated (0.22 μm PVDF membrane, Millipore) water
was used as a mobile phase with a flow rate of 0.15 mL min−1.
Separation was monitored by UV absorbance at 280 and
405 nm by operating software Biologic DuoFlow. Collected frac-
tions were lyophilized (FreeZone Freeze Dry System,
Labconco).
Recombinant arabinofuranosidase Araf51 was produced in
E. coli and purified as already described.47 The hydrolytic
activity toward p-nitrophenyl pyranosides was tested by incu-
bation of the solution of enzyme (obtained after aﬃnity Ni-
NTA chromatography and exchanged to 50 mM PBS pH 7.4 by
PD10 gel chromatography) with individual glycopyranosides
(5 mM) in 50 mM potassium phosphate buﬀer pH 7.4 at 60 °C.
The release of p-nitrophenolate was continuously measured at
405 nm (Microplate Spectrophotomerer PowerWave XS/XS2,
BioTek) and data evaluated with Gen5 Data Analysis Software
(BioTek). pNP α-D-Galp, pNP β-D-Galp, pNP α-D-Glcp, pNP
β-D-Glcp, pNP α-D-Manp, pNP β-D-Manp and pNP α-L-Rhap are
commercially available.
General procedure for the transglycosylation reactions
Prior to preparative-scale reactions, the time-course analyses
were performed in the analytical scale (5 μmol of individual
pNP pyranosides, 0.5 μmol of pNP β-D-galactofuranoside and
36 U of Araf51 in 100 μL of 50 mM PBS pH 7.4). The reaction
was monitored by TLC (7 : 2 : 2 EtOAc–AcOH–H2O). Preparative-
scale reactions were performed at 60 °C by incubation of the
pNP β-D-galactofuranoside (20 mg, 66 μmol; or 10 mg,
33 μmol) with individual pNP pyranosides (200 mg, 660 μmol
for pNP D-Glcp and pNP D-Galp; 100 mg, 330 μmol for pNP
D-Manp and pNP L-Rhap) and 4800 U of Araf51 (for reactions
with pNP D-Glcp and pNP D-Galp) or 2400 U of Araf51 (for reac-
tions with pNP D-Manp and pNP L-Rhap) in 50 mM PBS pH 7.4
in a total volume with regard to the solubility of substrates:
5 mL (reactions with α- and β-D-Galp and β-D-Glcp) or 10 mL
(α-D-Glcp and α- and β-D-Manp) or 15 mL (α-L-Rhap).
Based on the results from analytical-scale reactions, individ-
ual reactions proceeded for 20 min with the exception of
α-D-Manp (15 min) and β-D-Manp (25 min) to obtain the
maximum ratio of transglycosylation/hydrolysis. The reactions
were stopped by enzyme denaturation at 100 °C for 10 min.
The reaction products were repeatedly separated by silica gel
flash chromatography using EtOAc–AcOH–H2O in ratios from
15 : 1 : 1 to 40 : 1 : 1. Separations were monitored by TLC, frac-
tions corresponding to individual regioisomers were collected,
evaporated and lyophilized several times with intermediate
dissolving in H2O, finally in D2O and subjected to structural
analyses.
p-Nitrophenyl β-D-galactofuranosyl-(1→2)-α-D-glucopyrano-
side (9). This compound was obtained according to the
described general procedure by incubation of 20 mg (66 μmol)
of 1 with 200 mg (660 μmol) of pNP α-D-glucopyranoside 2 in
the presence of 4800 U of Araf51 and was isolated in 44% yield
(13.3 mg) after purification. TLC: Rf = 0.45 (AcOEt–AcOH–H2O,
7/2/2). 1H NMR (400 MHz, D2O): δ = 8.19 (d, 2H, J = 9.2 Hz,
Hm, C6H4), 7.23 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.87 (d, 1H, J =
3.6 Hz, 1a-H), 5.08 (d, 1H, J = 2.0 Hz, 1b-H), 4.07 (dd, 1H, J =
2.0, 4.2 Hz, 2b-H), 3.93 (dd, 1H, J = 4.2, 6.8 Hz, 3b-H), 3.92 (dd,
1H, J = 9.0, 9.8 Hz, 3a-H), 3.70 (dd, 1H, J = 3.6, 9.8 Hz, 2a-H),
3.60–3.50 (m, 3H, 6a-H, 5a-H), 3.56 (dd, 1H, J = 3.1, 6.8 Hz, 4b-
H), 3.53–3.47 (m, 1H, 5b-H), 3.50 (dd, 1H, J = 9.0, 9.8 Hz,
4a-H), 3.10 (dd, 1H, J = 8.1, 11.5 Hz, 6b-H), 2.86 (dd, 1H, J =
4.0, 11.5 Hz, 6′b-H) ppm. 13C NMR (100 MHz, D2O): δ = 161.6
(Cipso C6H4), 142.7 (Cp C6H4), 126.1 (Cm C6H4), 116.7
(Co C6H4), 109.5 (1b-C), 96.3 (1a-C), 82.6 (4b-C), 81.1 (2b-C), 79.3
(2a-C), 76.1 (3b-C), 72.4 (5a-C), 71.5 (3a-C), 69.7 (5b-C), 69.0
(4a-C), 62.7 (6b-C), 60.1 (6a-C) ppm. HRMS (ESI): m/z calcd for
C18H25O13NNa [M + Na]
+ 486.12181; found 486.12173.
p-Nitrophenyl β-D-galactofuranosyl-(1→3)-α-D-glucopyrano-
side (10). This compound was obtained according to the
described general procedure by incubation of 1 (20 mg,
66 μmol) with pNP α-D-glucopyranoside 2 (200 mg, 660 μmol)
in the presence of 4800 U of Araf51. It was isolated in 34%
yield (10.5 mg). TLC: Rf = 0.5 (AcOEt–AcOH–H2O, 7/2/2).
1H
NMR (400 MHz, D2O): δ = 8.12 (d, 2H, J = 9.2 Hz, Hm, C6H4),
7.18 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.70 (d, 1H, J = 3.5 Hz, 1a-
H), 5.24 (d, 1H, J = 1.5 Hz, 1b-H), 4.10 (dd, 1H, J = 1.5, 3.5 Hz,
2b-H), 4.03–3.99 (m, 2H, 3b-H, 4b-H), 3.96 (dd, 1H, J = 9.2,
9.6 Hz, 3a-H), 3.80 (dd, 1H, J = 3.5, 9.6 Hz, 2a-H), 3.76 (ddd,
1H, J = 3.2, 4.4, 7.6 Hz, 5b-H), 3.67–3.57 (m, 5H, 6a-H, 6′a-H,
6b-H, 6′b-H, 5a-H), 3.48 (dd, 1H, J = 9.2, 9.6 Hz, 4a-H) ppm.
13C NMR (100 MHz, D2O): δ = 161.1 (Cipso C6H4), 141.9 (Cp
C6H4), 125.7 (Cm C6H4), 116.4 (Co C6H4), 108.3 (1b-C), 96.6
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(1a-C), 82.9 (4b-C), 81.2 (2b-C), 79.4 (3a-C), 76.7 (3b-C), 72.7
(5a-C), 70.8 (2a-C), 70.6 (5b-C), 67.5 (4a-C), 62.8 (6b-C), 60.1
(6a-C) ppm. HRMS (ESI): m/z calcd for C18H25O13NNa
[M + Na]+ 486.12181; found 486.12160.
p-Nitrophenyl β-D-galactofuranosyl-(1→2)-β-D-glucopyrano-
side (11). This compound was obtained according to the
described general procedure by incubating 1 (20 mg, 66 μmol)
with pNP β-D-glucopyranoside 3 (200 mg, 660 μmol) in the
presence of 4800 U of Araf51, and was isolated in 26% yield
(7.9 mg). TLC: Rf = 0.4 (AcOEt–AcOH–H2O, 7/2/2).
1H NMR
(400 MHz, D2O): δ = 8.18 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.17 (d,
2H, J = 9.2 Hz, Ho, C6H4), 5.28 (d, 1H, J = 7.2 Hz, 1a-H), 5.26
(d, 1H, J = 1.4 Hz, 1b-H), 4.03 (dd, 1H, J = 1.4, 2.5 Hz, 2b-H),
3.94–3.90 (m, 2H, 3b-H, 4b-H), 3.81 (dd, 1H, J = 5.7, 12.4 Hz,
6a-H), 3.70–3.65 (m, 2H, 5b-H, 2a-H), 3.65 (dd, 1H, J = 9.5, 9.5
Hz, 3a-H), 3.64 (dd, 1H, J = 2.2, 12.4 Hz, 6′a-H), 3.59–3.55 (m,
1H, 5a-H), 3.44 (dd, 1H, J = 4.3, 11.6 Hz, 6b-H), 3.43 (t, 1H, J =
9.5 Hz, 4a-H), 3.39 (dd, 1H, J = 7.3, 11.6 Hz, 6′b-H) ppm. 13C
NMR (100 MHz, D2O): δ = 161.6 (Cipso C6H4), 142.7 (Cp C6H4),
126.1 (Cm C6H4), 116.5 (Co C6H4), 108.3 (1b-C), 98.1 (1a-C),
83.7 (4b-C), 81.0 (2b-C), 78.2 (2a-C), 76.7 (3b-C), 76.1 (5a-C),
75.6 (3a-C), 70.8 (5b-C), 69.0 (4a-C), 62.7 (6b-C), 60.3 (6a-C)
ppm. HRMS (ESI): m/z calcd for C18H25O13NNa [M + Na]
+
486.12181; found 486.12173.
p-Nitrophenyl β-D-galactofuranosyl-(1→3)-β-D-glucopyrano-
side (12). This disaccharide was prepared as described in the
general procedure starting from donor 1 (20 mg, 66 μmol) and
pNP β-D-glucopyranoside 3 (200 mg, 660 μmol) in the presence
of 4800 U of Araf51. The target compound 12 was isolated in
25% yield (7.6 mg) after purification. TLC: Rf = 0.48 (AcOEt–
AcOH–H2O, 7/2/2).
1H NMR (400 MHz, D2O): δ = 8.18 (d, 2H,
J = 9.2 Hz, Hm, C6H4), 7.17 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.26
(d, 1H, J = 1.7 Hz, 1b-H), 5.21 (d, 1H, J = 7.6 Hz, 1a-H), 4.10
(dd, 1H, J = 1.7, 3.3 Hz, 2b-H), 4.02 (dd, 1H, J = 3.8, 6.4 Hz, 4b-
H), 4.01 (ddd, 1H, J = 0.4, 3.3, 6.4 Hz, 3b-H), 3.87–3.84 (m, 1H,
6a-H), 3.77–3.72 (m, 1H, 5b-H), 3.72–3.68 (m, 1H, 3a-H),
3.70–3.66 (m, 2H, 2a-H, 6′a-H), 3.66–3.57 (m, 2H, 5a-H, 6b-H),
3.61–3.55 (m, 1H, 6′b-H), 3.49 (dd, 1H, 4a-H) ppm. 13C NMR
(100 MHz, D2O): δ = 161.6 (Cipso C6H4), 142.7 (Cp C6H4), 126.1
(Cm C6H4), 116.5 (Co C6H4), 108.1 (1b-C), 99.2 (1a-C), 83.0 (4b-
C), 81.5 (2a-C), 81.1 (2b-C), 76.6 (3b-C), 76.0 (5a-C), 72.8 (3a-C),
70.6 (5b-C), 67.7 (4a-C), 62.8 (6b-C), 60.5 (6a-C) ppm. HRMS
(ESI): m/z calcd for C18H25O13NNa [M + Na]
+ 486.12181; found
486.12171.
p-Nitrophenyl β-D-galactofuranosyl-(1→6)-β-D-glucopyrano-
side (13). This compound was synthesized as described in the
general procedure using 1 (20 mg, 66 μmol), pNP β-D-gluco-
pyranoside 3 (200 mg, 660 μmol), and 4800 U of Araf51. The
desired disaccharide 13 was isolated in 30% yield (9.2 mg).
TLC: Rf = 0.4 (AcOEt–AcOH–H2O, 7/2/2).
1H NMR (600 MHz,
D2O): δ = 8.22 (d, 2H, J = 9.1 Hz, Hm, C6H4), 7.21 (d, 2H, J = 9.1
Hz, Ho, C6H4), 5.22 (d, 1H, J = 2.7 Hz, 1a-H), 4.94 (d, 1H, J =
1.5 Hz, 1b-H), 4.04–3.97 (m, 2H, 6a-H, 2b-H), 4.98 (dd, 1H, J =
3.4, 6.2 Hz, 3b-H), 3.90–3.86 (m, 1H, 4b-H), 3.80–3.71 (m, 3H,
5a-H, 5b-H, 6′a-H), 3.57–3.48 (m, 5H, 3a-H, 2a-H, 6b-H, 6′b-H,
4a-H) ppm; 13C NMR (125 MHz, D2O): δ = 161.6 (Cipso C6H4),
142.7 (Cp C6H4), 126.1 (Cm C6H4), 116.5 (Co C6H4), 107.9 (1b-
C), 99.3 (1a-C), 83.0 (4b-C), 81.0 (2b-C), 76.8 (3b-C), 75.3 (3a-C),
75.2 (5a-C), 72.7 (2a-C), 70.8 (5b-C), 69.4 (4a-C), 66.3 (6a-C),
62.7 (6b-C) ppm. HRMS (ESI): m/z calcd for C18H25O13NNa
[M + Na]+ 486.12181; found 486.12172.
p-Nitrophenyl β-D-galactofuranosyl-(1→2)-α-D-galactopyrano-
side (14). This compound was obtained according to the
general procedure starting from donor 1 (20 mg, 66 μmol),
acceptor 4 (200 mg, 660 μmol) and 4800 U of Araf51. Com-
pound 14 was isolated in 41% yield (12.6 mg). TLC: Rf = 0.4
(AcOEt–AcOH–H2O, 7/2/2).
1H NMR (400 MHz, D2O): δ = 8.19
(d, 2H, J = 9.2 Hz, Hm, C6H4), 7.23 (d, 2H, J = 9.2 Hz, Ho,
C6H4), 5.89 (d, 1H, J = 3.2 Hz, 1a-H), 5.08 (s, 1H, 1b-H), 4.10
(dd, 1H, J = 3.3, 10.4 Hz, 3a-H), 4.07 (dd, 1H, J = 2.1, 4.3 Hz,
2b-H), 3.99 (dd, 1H, J = 2.0, 3.3 Hz, 4a-H), 3.93 (ddd, 1H, J =
0.7, 4.3, 6.9 Hz, 3b-H), 3.91 (dd, 1H, J = 3.7, 10.3 Hz, 2a-H),
3.89 (ddd, 1H, J = 1.9, 4.7, 7.7 Hz, 5a-H), 3.67–3.57 (m, 2H,
6a-H, 6′a-H), 3.56 (dd, 1H, J = 2.9, 6.9 Hz, 4b-H), 3.52 (ddd, 1H,
J = 2.9, 4.2, 8.2 Hz, 5b-H), 3.42 (dd, 1H, J = 4.0, 6.4 Hz, 6b-H),
3.11 (dd, 1H, J = 8.0, 11.2 Hz, 6′b-H) ppm. 13C NMR (100 MHz,
D2O): δ = 161.6 (Cipso C6H4), 142.7 (Cp C6H4), 126.2
(Cm C6H4), 116.8 (Co C6H4), 109.7 (1b-C), 96.6 (1a-C), 82.5
(4b-C), 81.2 (2b-C), 76.2 (2a-C and 3b-C), 71.8 (5a-C), 69.6
(5b-C), 69.0 (4a-C), 68.0 (3a-C), 62.6 (6b-C), 60.8 (6a-C) ppm.
HRMS (ESI): m/z calcd for C18H25O13NNa [M + Na]
+ 486.12181;
found 486.12163.
p-Nitrophenyl β-D-galactofuranosyl-(1→3)-α-D-galactopyrano-
side (15). The disaccharide 15 was obtained according to the
described general procedure by incubation of donor 1 (20 mg,
66 μmol) with acceptor 4 (200 mg, 660 μmol) in the presence
of 4800 U of Araf51, and was isolated in regioisomeric mixture
with 16 in 32% yield (9.9 mg). According to the 1H NMR signal
integration, it was obtained in 18% yield. TLC: Rf = 0.48
(AcOEt–AcOH–H2O, 7/2/2).
1H NMR (400 MHz, D2O): δ = 8.19
(d, 2H, J = 9.2 Hz, Hm, C6H4), 7.23 (d, 2H, J = 9.2 Hz, Ho,
C6H4), 5.74 (d, 1H, J = 3.8 Hz, 1a-H), 5.12 (d, 1H, J = 2.1 Hz,
1b-H), 4.10 (dd, 1H, J = 3.7, 10.2 Hz, 3a-H), 4.07 (dd, 1H, J =
2.2, 4.7 Hz, 2b-H), 4.02 (dd, 1H, J = 1.3, 3.0 Hz, 4a-H), 3.97 (dd,
1H, J = 3.7, 10.4 Hz, 2a-H), 3.95 (dd, 1H, J = 4.4, 7.1 Hz, 3b-H),
3.92–3.87 (m, 1H, 5a-H), 3.85 (dd, 1H, J = 3.7, 7.1 Hz, 4b-H),
3.72–3.67 (m, 1H, 5b-H), 3.57–3.50 (m, 4H, 6a-H, 6′a-H, 6b-H,
6′b-H) ppm; 13C NMR (100 MHz, D2O): δ = 161.6 (Cipso C6H4),
142.7 (Cp C6H4), 126.2 (Cm C6H4), 116.8 (Co C6H4), 108.9 (1b-
C), 96.6 (1a-C), 82.2 (4b-C), 81.4 (2b-C), 76.1 (3b-C), 75.6 (4a-C),
71.9 (5a-C), 70.1 (5b-C), 69.6 (3a-C), 67.8 (2a-C), 62.7 (6b-C),
61.3 (6a-C) ppm. HRMS (ESI): m/z calcd for C18H25O13NNa
[M + Na]+ 486.12181; found 486.12161.
p-Nitrophenyl β-D-galactofuranosyl-(1→4)-α-D-galactopyrano-
side (16). This compound was synthesized according to the
described general procedure starting from 1 (20 mg, 66 μmol),
pNP α-D-galactopyranoside 4 (200 mg, 660 μmol), 4800 U of
Araf51, and was isolated in regioisomeric mixture with 15 in
32% yield (9.9 mg). According to the 1H NMR signal inte-
gration, this compound was obtained in 14% yield. TLC: Rf =
0.5 (AcOEt–AcOH–H2O, 7/2/2).
1H NMR (400 MHz, D2O): δ =
8.19 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.23 (d, 2H, J = 9.2 Hz, Ho,
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C6H4), 5.75 (d, 1H, J = 3.2 Hz, 1a-H), 5.15 (d, 1H, J = 1.8 Hz, 1b-
H), 4.10 (dd, 1H, J = 1.8, 3.6 Hz, 2b-H), 4.09–4.02 (m, 2H, 4a-H,
3a-H), 4.03 (dd, 1H, J = 3.3, 10.4 Hz, 2a-H), 3.96 (ddd, 1H, J =
0.9, 3.4, 6.7 Hz, 3b-H), 3.94 (dd, 1H, J = 4.0, 6.6, 4a-H),
3.90–3.86 (m, 1H, 5a-H), 3.74–3.68 (m, 1H, 5b-H), 3.58–3.52
(m, 4H, 6a-H, 6′a-H, 6b-H, 6′b-H) ppm; 13C NMR (100 MHz,
D2O): δ = 161.6 (Cipso C6H4), 142.7 (Cp C6H4), 126.2 (Cm
C6H4), 116.8 (Co C6H4), 109.2 (1b-C), 96.6 (1a-C), 82.7 (4b-C),
81.4 (2b-C), 76.7 (3b-C), 72.0 (3a-C), 71.9 (5a-C), 71.9 (5a-C),
70.6 (5b-C), 66.9 (2a-C), 62.6 (6b-C), 60.8 (6a-C) ppm. HRMS
(ESI): m/z calcd for C18H25O13NNa [M + Na]
+ 486.12181; found
486.12162.
p-Nitrophenyl β-D-galactofuranosyl-(1→2)-β-D-galactopyrano-
side (17). The disaccharide was synthesized as described in
the general procedure incubating furanosyl donor 1 (20 mg,
66 μmol) with pNP β-D-galactopyranoside 5 (200 mg, 660 μmol)
in the presence of 4800 U of Araf51, and was isolated in 27%
yield (8.1 mg). TLC: Rf = 0.4 (AcOEt–AcOH–H2O, 7/2/2).
1H
NMR (400 MHz, D2O): δ = 8.18 (d, 2H, J = 9.2 Hz, Hm, C6H4),
7.17 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.25 (d, 1H, J = 1.5 Hz,
1b-H), 5.24 (d, 1H, J = 7.5 Hz, 1a-H), 4.05 (dd, 1H, J = 2.9, 1.5
Hz, 2b-H), 3.95 (dd, 1H, J = 2.9, 5.8 Hz, 3b-H), 3.96–3.91 (m,
1H, 5a-H), 3.91 (dd, 1H, J = 4.1, 5.8 Hz, 4b-H), 3.88 (dd, 1H, J =
7.5, 9.7 Hz, 2a-H), 3.84–3.78 (m, 2H, 3a-H, 4a-H), 3.73–3.67 (m,
3H, 5b-H, 6a-H, 6′a-H), 3.45 (dd, 1H, J = 4.4, 11.7 Hz, 6b-H),
3.39 (dd, 1H, J = 7.3, 11.7 Hz, 6′b-H) ppm. 13C NMR (100 MHz,
D2O): δ = 161.9 (Cipso C6H4), 142.6 (Cp C6H4), 125.9 (Cm
C6H4), 116.4 (Co C6H4), 108.4 (1a-C), 98.5 (1b-C), 83.5 (4a-C),
81.0 (2a-C), 76.7 (3a-C), 76.4 (2b-C), 75.5 (4b-C), 72.6 3b-C),
70.8 (5a-C), 68.4 (5b-C), 62.6 (6a-C), 60.6 (6b-C) ppm. HRMS
(ESI): m/z calcd for C18H25O13NNa [M + Na]
+ 486.12181; found
486.12190.
p-Nitrophenyl β-D-galactofuranosyl-(1→6)-β-D-galactopyrano-
side (18). This compound was prepared according to the
described general procedure by incubation of 1 (20 mg,
66 μmol) with of pNP β-D-galactopyranoside 5 (200 mg,
660 μmol) in the presence of 4800 U of Araf51, and was iso-
lated in 25% yield (7.6 mg). TLC: Rf = 0.4 (AcOEt–AcOH–H2O,
7/2/2). 1H NMR (400 MHz, D2O): δ = 8.18 (d, 2H, J = 9.2 Hz,
Hm, C6H4), 7.17 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.12 (d, 1H, J =
7.6 Hz, 1a-H), 4.90 (dd, 1H, J = 1.2, 0.6 Hz, 1b-H), 4.00 (ddd,
1H, J = 0.9, 3.8, 8.4 Hz, 4a-H), 3.97 (d, 1H, J = 1.2 Hz, 2b-H),
3.96 (ddd, 1H, J = 3.3, 0.6 Hz, 3b-H), 3.93 (dd, 1H, J = 0.9, 3.4
Hz, 4a-H), 3.91 (dd, 1H, J = 1.5, 4.4 Hz, 4b-H), 3.83 (dd, 1H, J =
3.8, 11.6 Hz, 6a-H), 3.76 (dd, 1H, J = 7.6, 9.9 Hz, 2a-H),
3.73–3.72 (m, 1H, 5b-H), 3.71 (dd, 1H, J = 8.4, 11.6 Hz, 6′a-H),
3.70 (dd, 1H, J = 3.4, 9.9 Hz, 3a-H), 3.63–3.57 (m, 1H, 6b-H),
3.56–3.51 (m, 1H, 6′b-H) ppm. 13C NMR (100 MHz, D2O): δ =
161.6 (Cipso C6H4), 142.7 (Cp C6H4), 126.1 (Cm C6H4), 116.5
(Co C6H4), 107.8 (1b-C), 99.8 (1a-C), 83.1 (4b-C), 82.0 (2b-C),
76.7 (3b-C), 74.5 (5a-C), 72.3 (3a-C), 70.7 (5b-C), 70.2 (2a-C),
68.5 (4a-C), 66.9 (6a-C), 62.5 (6b-C) ppm. HRMS (ESI): m/z
calcd for C18H25O13NNa [M + Na]
+ 486.12181; found
486.12172.
p-Nitrophenyl β-D-galactofuranosyl-(1→6)-α-D-mannopyrano-
side (19). This compound was prepared according to the
described general procedure by incubation of 1 (20 mg,
66 μmol) with of pNP α-D-mannopyranoside 6 (200 mg,
660 μmol) in the presence of 4800 U of Araf51, and was iso-
lated in 15% yield (4.6 mg). 1H NMR (600 MHz, D2O): δ = 8.22
(d, 2H, J = 9.3 Hz, Hm, C6H4), 7.23 (d, 2H, J = 9.3 Hz, Ho,
C6H4), 5.71 (d, 1H, J = 1.7 Hz, 1a-H), 4.91 (d, 1H, J = 1.7 Hz, 1b-
H), 4.14 (dd, 1H, J = 1.7, 3.4 Hz, 2a-H), 3.99 (dd, 1H, J = 3.4, 9.1
Hz, 3a-H), 3.91–3.82 (m, 3H, 5a-H, 2b-H, 3b-H), 3.72–3.62 (m,
3H, 4a-H, 6a-H, 6a′-H), 3.62–3.56 (m, 1H, 5b-H), 3.52–3.44 (m,
3H, 4b-H, 6b-H, 6a′-H) ppm. 13C NMR (125 MHz, D2O): δ =
160.7 (Cipso C6H4), 142.0 (Cp C6H4), 126.0 (Cm C6H4), 116.8
(Co C6H4), 108.1 (1b-C), 97.6 (1a-C), 82.5 (4b-C), 81.1 (2b-C),
76.5 (3b-C), 73.2 (4a-C), 70.5 (5b-C), 70.2 (3a-C), 69.6 (2a-C),
67.3(6a-CH2), 66.7 (5a-C), 62.8 (6b-CH2) ppm.
p-Nitrophenyl β-D-galactofuranosyl-(1→4)-β-D-mannopyrano-
side (20). This compound was obtained according to the
general procedure by incubation of 1 (10 mg, 33 μmol) with
mannopyranosidic acceptor 7 (100 mg, 330 μmol) in the pres-
ence of 2400 U of Araf51, and was isolated in 49% yield
(7.5 mg). TLC: Rf = 0.49 (AcOEt–AcOH–H2O, 7/2/2).
1H NMR
(400 MHz, D2O): δ = 8.16 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.13 (d,
2H, J = 9.2 Hz, Ho, C6H4), 5.43 (s, 1H, 1a-H), 5.02 (d, 1H, J =
1.80 Hz, 1b-H), 4.18 (d, 1H, J = 2.6 Hz, 2a-H), 4.06–4.03 (m, 2H,
4b-H, 3b-H), 4.02 (d, 1H, 2b-H), 3.87 (dd, 1H, J = 1.9, 12.2 Hz,
6a-H), 3.79 (dd, 1H, J = 2.6, 9.2 Hz, 3a-H), 3.80–3.76 (m, 1H,
4a-H), 3.75–3.73 (m, 1H, 5b-H), 3.72 (dd, 1H, J = 4.5, 12.2 Hz,
6′a-H), 3.63 (ddd, 1H, J = 1.9, 5.4, 9.5 Hz, 5a-H), 3.60 (d, 1H, J =
6.7, 11.9 Hz, 6b-H), 3.58 (dd, 1H, J = 4.1, 11.9 Hz, 6′b-H) ppm.
13C NMR (100 MHz, D2O): δ = 161.5 (Cipso C6H4), 142.4 (Cp
C6H4), 126.1 (Cm C6H4), 116.2 (Co C6H4), 108.0 (1b-C), 97.0
(1a-C), 82.8 (3b-C), 81.0 (4b-C), 76.0 (2b-C), 74.6 (4a-C), 71.2
(3a-C), 70.5 (5b-C), 70.1 (2a-C), 62.6 (6b-C), 61.1 (5a-C), 60.3
(6a-C) ppm. HRMS (ESI): m/z calcd for C18H25O13NNa [M +
Na]+ 486.12181; found 486.12204.
p-Nitrophenyl β-D-galactofuranosyl-(1→6)-β-D-mannopyrano-
side (21). This compound was prepared according to the
described general procedure by incubation of 1 (20 mg,
66 μmol) with of pNP α-D-mannopyranoside 6 (200 mg,
660 μmol) in the presence of 4800 U of Araf51, and was iso-
lated in 15% yield (4.9 mg). 1H NMR (600 MHz, D2O): δ = 8.20
(d, 2H, J = 9.3 Hz, Hm, C6H4), 7.17 (d, 2H, J = 9.3 Hz, Ho,
C6H4), 5.46 (br s, 1H, 1a-H), 4.95 (d, J = 4.4 Hz, 1H, 1b-H), 4.18
(d, 1H, J = 3.0 Hz, 2a-H), 4.00–3.00 (m, 2H, 5a-H, 2b-H), 3.97
(dd, 1H, J = 3.5, 6.0 Hz, 3b-H), 3.91 (dd, 1H, J = 4.3, 6.0 Hz, 4b-
H), 3.76–3.63 (m, 5H, 3a-H, 4a-H, 5b-H, 6a-H, 6a′-H), 3.60–3.53
(m, 2H, 6b-H, 6b′-H) ppm. 13C NMR (125 MHz, D2O): δ = 161.5
(Cipso C6H4), 142.5 (Cp C6H4), 126.1 (Cm C6H4), 116.3
(Co C6H4), 107.9(1b-C), 97.0 (1a-C), 83.1 (4b-C), 80.9 (2b-C),
76.8 (3b-C), 75.5 (4a-C), 72.5 (3a-C), 70.8 (5b-C), 70.2 (2a-C),
66.6 (5a-C), 66.6 (6a-CH2), 62.7 (6b-CH2) ppm.
p-Nitrophenyl β-D-galactofuranosyl-(1→4)-α-L-rhamnopyra-
noside (22). This compound was obtained according to the
described general procedure by incubation of pNP β-D-galacto-
furanoside 1 (10 mg, 33 μmol) with pNP α-L-rhamnopyranoside
8 (100 mg, 330 μmol) in the presence of 2400 U of Araf51, and
was isolated in 38% yield (5.5 mg). TLC: Rf = 0.5 (AcOEt–
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AcOH–H2O, 7/2/2).
1H NMR (400 MHz, D2O): δ = 8.15 (d, 2H,
J = 9.2 Hz, Hm, C6H4), 7.13 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.55
(d, 1H, J = 1.2 Hz, 1a-H), 5.21 (d, 1H, J = 1.7 Hz, 1b-H), 4.06
(dd, 1H, J = 1.2, 3.4 Hz, 2a-H), 4.04 (dd, 1H, J = 1.8, 3.9 Hz, 2b-
H), 4.04–4.00 (m, 1H, 3a-H), 3.97 (dd, 1H, J = 3.9, 6.3 Hz,
3b-H), 3.87 (dd, J = 3.8, 6.3 Hz, 1H, 4b-H), 3.72 (ddd, J = 4.4,
4.5, 7.2 Hz, 1H, 5b-H), 3.58 (dd, 1H, J = 4.4, 11.6 Hz, 6b-H),
3.59–3.55 (m, 1H, 5a-H), 3.57–3.53 (m, 1H, 4a-H), 3.54 (dd, 1H,
J = 7.2, 11.6 Hz, 6′b-H), 1.11 (d, 1H, J = 5.7 Hz, CH3) ppm.
13C
NMR (100 MHz, D2O): δ = 161.3 (Cipso C6H4), 142.0 (Cp C6H4),
125.8 (Cm C6H4), 116.2 (Co C6H4), 108.4 (1b-C), 97.5 (1a-C),
82.7 (4b-C), 81.5 (2b-C), 77.8 (4a-C), 70.4 (5b-C), 70.3 (3a-C),
69.9 (2a-C), 68.2 (5a-C), 62.7 (6b-C), 17.1 (6a-C) ppm. HRMS
(ESI): m/z calcd for C18H25O12NNa [M + Na]
+ 470.12690; found
470.12665.
Molecular modeling
All simulations were performed in Gromacs 4.5.5.48 Each
system included one molecule of Araf51 (from the experi-
mental structure, PDB I.D. 2C8N),49 one molecule of putative
transglycosylation product, ∼18 300 water molecules and 15
sodium counter-ions. Protein was modelled using Amber99SB
force field,50 transglycosylation products were modelled using
Glycam0651 (carbohydrates) and General Amber Force Field52
(pNP-moiety). Charges were calculated by RESP method on the
basis of HF/6-31G*//HF/6-31G* wavefunction calculated for
individual fragments in Gaussian 03.53 Molecules of putative
products were placed to the active site by 3D-alignment of the
Galf moiety with the Araf moiety in the experimental structure.
This was followed by manual adjustment of glycosidic bond
torsions to avoid steric clashes. Finally, the system was mini-
mized (3000 steps of L-BFGS and 500 steps of steepest descent)
and simulated by 1 ns of equilibration and 10 ns of production
simulation. Non-hydrogen atoms of the protein and Galf were
restrained during the equilibration run by a harmonic restraint
potential.
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